PWM
GRCE

Palumbo Wealth Management’s Grace Therapeutics GRCE Stock Holding History

Palumbo Wealth Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-48,541
Closed -$144K – 234
2025
Q2 		$144K Buy
48,541
+2,534
+6% +$6.74K 0.04% 192
2025
Q1 		$105K Buy
+46,007
New +$145K 0.04% 181

Other funds holding GRCE

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $254M AUM 29.05% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Palumbo Wealth Management's GRCE Position: Q3 2025 in Review

Palumbo Wealth Management sold out of Grace Therapeutics (GRCE) in Q3 2025, closing a stake of 48,541 shares — an estimated $144K sold.

Palumbo Wealth Management first reported a position in GRCE in Q1 2025 and held it in 2 quarters. The position peaked at $144K in Q2 2025. 20 funds tracked by Wall St. Rank hold GRCE as of Q3 2025.

  • Palumbo Wealth Management reported no remaining Grace Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Palumbo Wealth Management sold 48,541 Grace Therapeutics shares in Q3 2025, an estimated $144K.
  • Palumbo Wealth Management first reported a position in Grace Therapeutics in Q1 2025 and held it in 2 quarters.
  • Palumbo Wealth Management's Grace Therapeutics position peaked at $144K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2025.

Based on Palumbo Wealth Management's 13F filing for Q3 2025, filed 10 Nov 2025.